Synthetic Biologics Announces Positive Topline Results from First Phase 2a Clinical Trial of SYN-004, the Company's Candidate for the Prevention of C. difficile Infection

-- SYN-004 Degraded IV Ceftriaxone in Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream --
-- First Patients Dosed in Phase 2b Proof-of-Concept Clinical Trial for SYN-004 --
-- SYN to Host Microbiome Clinical Program Seminar in NYC on Thursday, December 10, 2015 --

http://finance.yahoo.com/news/synthetic-biolo...00229.html